17812-32-7

Basic information

• Product Name: 1-Methyl L-aspartate
• Synonyms: L-ASPARTIC ACID ALPHA-METHYL ESTER;ASPARTIC ACID-OME;H-ASP-OME;L-ASPARTIC ACID-1-METHYL ESTER;1-Methyl L-Aspartate;3-Amino-4-methoxy-4-oxobutanoic acid;ASP(OMe);Aspartic acid 1-methyl ester
• CAS NO: 17812-32-7
• Molecular Formula: C₅H₉NO₄
• Molecular Weight: 147.13
• Product Categories: Amino Acids Derivatives;Aspartic acid [Asp, D];Amino Acids and Derivatives;Amino Acid Methyl Esters;Amino Acids;Amino Acids (C-Protected);Biochemistry
• Mol File: 17812-32-7.mol

Chemical Properties

• Melting Point: 186 °C
• Boiling Point: 272.7 °C at 760 mmHg
• Flash Point: 118.7 °C
• Appearance: White/Powder
• Density: 1.299 g/cm³
• Vapor Pressure: 0.00166mmHg at 25°C
• Refractive Index: 36 ° (C=0.5, H2O)
• Storage Temp.: 2-8°C
• PKA: 3.45±0.19(Predicted)
• Water Solubility: Soluble in water
• CAS DataBase Reference: 1-Methyl L-aspartate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl L-aspartate(17812-32-7)
• EPA Substance Registry System: 1-Methyl L-aspartate(17812-32-7)

Safety Data

• Hazardous Substances Data: 17812-32-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl L-aspartate is used as an active pharmaceutical ingredient for its potential role in modulating neurotransmission. It may be utilized in the development of drugs targeting the central nervous system, particularly those aimed at treating conditions related to neurotransmitter imbalances.
Used in Nutraceutical Industry:
1-Methyl L-aspartate is used as a dietary supplement ingredient due to its association with L-Aspartic Acid, which is known to contribute to protein synthesis and overall health. It may be included in products designed to support cognitive function, energy production, and general well-being.
Used in Research Applications:
1-Methyl L-aspartate is used as a research tool for studying the role of L-aspartate as an excitatory neurotransmitter in the central nervous system. It can be employed in laboratory experiments to investigate the mechanisms of neurotransmission and the development of novel therapeutic strategies for neurological disorders.
Used in Food Industry:
1-Methyl L-aspartate may be used as an additive in the food industry to enhance flavor or as a component in the production of certain food products, leveraging its connection to L-Aspartic Acid, which is naturally present in various food sources.

InChI:InChI=1/C5H9NO4/c1-10-5(9)3(6)2-4(7)8/h3H,2,6H2,1H3,(H,7,8)/t3-/m0/s1

Upstream product

• 67-56-1 methanol 
• 5487-35-4 (S)-3-amino-dihydro-furan-2,5-dione; hydrobromide 
• 65414-63-3 N-phenacetyl L-aspartic acid α-methyl ester 
• 35909-97-8 (S)-2-Benzyloxycarbonylamino-succinic acid 4-benzyl ester 1-methyl ester 
• 34029-31-7 (S)-3-amino-3,4-dihydrofurane-2,5-dione hydrochloride 
• 56-84-8 L-Aspartic acid 
• 131021-87-9 <(4S)-2,2-bis(trifluoromethyl)-5-oxo-1,3-oxazolidine-4-yl>acetate 
• 4668-42-2 (S)-2-benzyloxycarbonylamino-succinic acid 1-methyl ester 
• 60504-59-8 N-Formyl-L-aspartic acid α-methyl ester 

Downstream Products

• 1338053-54-5 C₃₀H₂₉N₃O₆ 
• 1338053-57-8 C₃₁H₃₁N₃O₆ 
• 1338053-58-9 C₃₅H₃₉N₃O₆ 
• 1338053-62-5 C₃₇H₄₁N₃O₈ 
• 1338053-63-6 C₃₆H₄₀N₄O₈ 
• 1338053-61-4 C₃₈H₃₇N₃O₇ 
• 76-05-1 trifluoroacetic acid 
• 39895-10-8 L-aspartic acid β-tert-butyl ester α-methyl ester 

Relevant articles and documents

NOVEL PYRROLO-LACTONE AND PYRROLE COMPOUNDS INDUCING CELLULAR GLUTATHIONE RECOVERY EFFECT AGAINST REACTIVE OXYGEN SPECIES, AND METHOD FOR PREPARING THE SAME

The present invention provides: a novel pyrrolo-lactone compound, which can be used as an improved pain therapeutic agent containing various substituents by using glucose and ribose as reducing sugars and conducting a reaction with various kinds of natural and unnatural amino acids; and novel pyrrolo compounds produced during a process of manufacturing the same. The novel pyrrolo-lactone and pyrrole compounds are substances which can be used as improved pain therapeutic agent by having increased restoration ability of glutathione in living cells against reactive oxygen species.COPYRIGHT KIPO 2019

A polypeptide material aspartic acid tert-butyl β - α - methyl ester hydrochloride preparation method

The invention discloses a polypeptide material aspartic acid tert-butyl β - α - methyl ester hydrochloride of the preparation method, is mainly composed of complex technology, cycle is long, the yield is low, the cost is high, the risk is high, does not meet the technical problems of production and the like. Preparation method of this invention comprises the following steps: 1st step, the aspartic acid suspended in dry tetrahydrofuran, in phosphorus oxychloride under the action of the aspartic acid in the preparation into the anhydride hydrochloride; 2nd step, aspartic acid anhydride hydrochloride suspended in methanol reaction to obtain the aspartic acid α - methyl ester hydrochloride, triethylamine for adjusting pH value so that the aspartic acid methyl α - separated out; 3rd step, aspartic acid methyl α - suspended in methylene chloride, access isobutene, concentrated sulfuric, sealed reaction to obtain the oil of aspartic acid tert-butyl methyl α - β -; 4th step, the oil of aspartic acid tert-butyl methyl α - β - dissolved in ethyl ether, dropping ethyl ether - hydrochloric acid gas, the final product is obtained α - β - tert-butyl aspartic acid methyl ester hydrochloride.

Design, synthesis, and molecular docking studies of N-(9,10-anthraquinone-2-carbonyl)amino acid derivatives as xanthine oxidase inhibitors

A series of N-(9,10-anthraquinone-2-carbonyl)amino acid derivatives (1a–j) was designed and synthesized as novel xanthine oxidase inhibitors. Among them, the L/D-phenylalanine derivatives (1d and 1i) and the L/D-tryptophan derivatives (1e and 1j) were effective with micromolar level potency. In particular, the L-phenylalanine derivative 1d (IC50?=?3.0?μm) and the D-phenylalanine derivative 1i (IC50?=?2.9?μm) presented the highest potency and were both more potent than the positive control allopurinol (IC50?=?8.1?μm). Preliminary SAR analysis pointed that an aromatic amino acid fragment, for example, phenylalanine or tryptophan, was essential for the inhibition; the D-amino acid derivative presented equal or greater potency compared to its L-enantiomer; and the 9,10-anthraquinone moiety was welcome for the inhibition. Molecular simulations provided rational binding models for compounds 1d and 1i in the xanthine oxidase active pocket. As a result, compounds 1d and 1i could be promising lead compounds for further investigation.

Parietic acid derivative and its synthesis and use

The invention relates to rheinic acid derivatives, and a synthetic method and applications thereof. The invention specifically discloses a compound with a general formula represented by formula (I), pharmaceutically acceptable salts and pharmaceutical compositions of the novel compound, and applications of the novel compound, the pharmaceutically acceptable salts and the pharmaceutical compositions in preparation of antitumor drugs, wherein R is used for representing L-amino acid amino C1-C6 alkyl, amino C2-C6 alkenyl, amino C3-C6 alkynyl, nitrogen-containing heterocyclic radical, or nitrogen-containing heterocyclic aryl group.

Synthesis of β-lactam peptidomimetics through Ugi MCR: First application of chiral Nβ-Fmoc amino alkyl isonitriles in MCRs

Chiral Nβ-Fmoc amino alkyl isonitriles were employed in Ugi multi component reactions (Ugi 4C-3CR) to obtain functionalized β-lactam peptidomimetics with l-aspartic acid α-methyl ester/peptide ester and organic aldehydes. The reactions were carried out in MeOH. Thirteen Ugi products have been prepared in good to moderate yields with good diastereoselectivities.

Hexafluoroacetone as protection and activation reagent in amino acid and peptide chemistry regiospecific α-functionalization of aspartic acid

A highly efficient method for regiospecific α-functionalization of aspartic acid is described. Key step is the synthesis of a N-protected and regioselectively α-carboxy-activated heterocyclic intermediate from aspartic acid and hexafluoroacetone. The new strategy offers i.a. a two step access to the sweetener Aspartame and to libraries of aspartame analogues.

IMMOBILIZED PENICILLINACYLASE: APPLICATION TO THE SYNTHESIS OF THE DIPEPTIDE ASPARTAME

Immobilized penicillinacylase efficently catalyzes the conversion at pH 7.5 of N-phenacetyl aspartame (4) into aspartame (2) and phenylacetic acid.

Method of removing formyl groups from N-formyl-amino acid and N-formyl-peptide esters

The masking N-formyl group of an N-formyl-amino acid ester or N-formyl-peptide ester is removed without major side reactions when the ester is reacted in an inert liquid medium with hydroxylamine of which at least 70% is present in the form of a salt with a strong acid, the remainder, if any, being present as the free base or the salt of a weak acid.